The impairment of β-lap’s ability to activate SIRT1-FOXO1 apoptotic pathway in HT29 cells due to glucuronidation hints that UGTs high expression in cancer cells may affect the responses to many therapeutic drugs. The gene discussed is FOXO1; the disease is cancer.